Skip to content

Dr. Gearóid Tuohy

Book Review of Low Vision-Principles and Management, 1st edition (Elsevier); by Christine Dickinson, Ana Hernandez Trillo and Michael Crossland

According to the Royal College of Ophthalmologists, the term of “low vision” is not defined in UK legislation however, the UK Low Vision Services Consensus… Read More »Book Review of Low Vision-Principles and Management, 1st edition (Elsevier); by Christine Dickinson, Ana Hernandez Trillo and Michael Crossland

Genentech (Roche Group) announce that FDA has approved the introduction of Susimvo (ranibizumab injection, ocular implant) for wet age-related macular degeneration. 

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), have announced the reintroduction of “Susvimo” (ranibizumab injection) 100 mg/mL for intravitreal use… Read More »Genentech (Roche Group) announce that FDA has approved the introduction of Susimvo (ranibizumab injection, ocular implant) for wet age-related macular degeneration. 

Early warning signs of diabetic retinopathy (DR) in clinics shows exponentially increases in prevalence on type 1 DR and type 2 DR.

Researchers at the Center for Ophthalmic Bioinformatics Research at the Cole Eye Institute, Cleveland, Ohio, have reported that the prevalence of diabetic retinopathy (DR) changed… Read More »Early warning signs of diabetic retinopathy (DR) in clinics shows exponentially increases in prevalence on type 1 DR and type 2 DR.

AAV treatment or surgical issues on chorioretinal atrophy? Researchers report on a study on potential adverse events in a gene therapy treatment.

Researchers based at the Nuffield Department of Clinical Neurosciences, The John Radcliffe Hospital, University of Oxford, have reported a new study on the mechanism of… Read More »AAV treatment or surgical issues on chorioretinal atrophy? Researchers report on a study on potential adverse events in a gene therapy treatment.

Nanoscope Therapeutics Inc., provides a commercial update on  MCO-010 treatment of retinitis pigmentosa (RP) using optogenetic therapy. 

Nanoscope Therapeutics Inc., a company based in Bedford, Texas, has provided an update following recent regulatory discussions with the U.S. Food and Drug Administration (“FDA”)… Read More »Nanoscope Therapeutics Inc., provides a commercial update on  MCO-010 treatment of retinitis pigmentosa (RP) using optogenetic therapy. 

USH2A: self-reported functional vision measured in associated retinal degeneration by the Michigan Retinal Degeneration Questionnaire (MRDQ).

Researchers for the Foundation Fighting Blindness (FFB) Clinical Consortium Investigator Group, based in Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan,… Read More »USH2A: self-reported functional vision measured in associated retinal degeneration by the Michigan Retinal Degeneration Questionnaire (MRDQ).

Opus Genetics Inc., has announced completion of dowsing in first cohort Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.

Opus Genetics Inc., a private ocular gene therapy company based in Raleigh, North Carolina, has announced the completion in the first cohort for a Phase… Read More »Opus Genetics Inc., has announced completion of dowsing in first cohort Phase 1/2 trial for “OPGx-LCA5” for the treatment of LCA5 retinal disease.